Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Meningococcal Vaccines | 5 | 2019 | 225 | 2.47 | Why? |
| Neisseria meningitidis | 2 | 2019 | 229 | 1.30 | Why? |
| Meningococcal Infections | 3 | 2018 | 216 | 0.81 | Why? |
| Streptococcal Vaccines | 1 | 2019 | 31 | 0.81 | Why? |
| Meningitis, Bacterial | 2 | 2019 | 111 | 0.80 | Why? |
| Immunity, Maternally-Acquired | 2 | 2018 | 179 | 0.77 | Why? |
| Bacterial Capsules | 1 | 2018 | 39 | 0.76 | Why? |
| Polysaccharides, Bacterial | 1 | 2018 | 59 | 0.75 | Why? |
| Parechovirus | 1 | 2018 | 48 | 0.74 | Why? |
| Streptococcus agalactiae | 1 | 2019 | 194 | 0.72 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2017 | 66 | 0.68 | Why? |
| Meningitis, Viral | 1 | 2018 | 97 | 0.68 | Why? |
| Gram-Positive Bacteria | 1 | 2018 | 230 | 0.67 | Why? |
| Pneumococcal Vaccines | 3 | 2019 | 571 | 0.66 | Why? |
| Antigens, Bacterial | 2 | 2018 | 330 | 0.63 | Why? |
| Meningitis, Meningococcal | 1 | 2017 | 114 | 0.62 | Why? |
| Meningitis | 1 | 2018 | 163 | 0.62 | Why? |
| Streptococcus pneumoniae | 2 | 2019 | 827 | 0.57 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.56 | Why? |
| Enterovirus | 1 | 2018 | 402 | 0.56 | Why? |
| Infant, Newborn, Diseases | 1 | 2018 | 394 | 0.53 | Why? |
| Antibodies, Bacterial | 4 | 2018 | 510 | 0.53 | Why? |
| Enterovirus Infections | 1 | 2018 | 404 | 0.52 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.47 | Why? |
| Body Temperature | 1 | 2017 | 875 | 0.46 | Why? |
| Immunization | 2 | 2021 | 2019 | 0.40 | Why? |
| British Columbia | 2 | 2021 | 512 | 0.38 | Why? |
| Vaccines | 3 | 2021 | 3692 | 0.32 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.32 | Why? |
| Infant | 15 | 2021 | 30274 | 0.31 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.28 | Why? |
| Vaccination | 5 | 2021 | 19050 | 0.28 | Why? |
| Papillomavirus Vaccines | 2 | 2020 | 405 | 0.26 | Why? |
| Status Epilepticus | 1 | 2008 | 303 | 0.26 | Why? |
| Infant, Newborn | 11 | 2020 | 23105 | 0.26 | Why? |
| Child, Preschool | 12 | 2021 | 36283 | 0.23 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.22 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.21 | Why? |
| Papillomavirus Infections | 2 | 2020 | 861 | 0.21 | Why? |
| Encephalitis | 2 | 2019 | 797 | 0.21 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.21 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.19 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.19 | Why? |
| Serogroup | 2 | 2018 | 510 | 0.18 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.18 | Why? |
| Whooping Cough | 1 | 2020 | 201 | 0.17 | Why? |
| Spinal Puncture | 1 | 2018 | 95 | 0.17 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Mutation Rate | 1 | 2018 | 382 | 0.15 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.15 | Why? |
| Intensive Care Units, Pediatric | 2 | 2020 | 1098 | 0.15 | Why? |
| Complement System Proteins | 1 | 2018 | 380 | 0.14 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.14 | Why? |
| Child | 10 | 2020 | 70012 | 0.13 | Why? |
| Risk-Taking | 1 | 2018 | 508 | 0.13 | Why? |
| Immunization Schedule | 2 | 2020 | 1305 | 0.13 | Why? |
| Humans | 28 | 2021 | 930598 | 0.12 | Why? |
| Mothers | 2 | 2020 | 1624 | 0.12 | Why? |
| Intention | 1 | 2021 | 1380 | 0.12 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.11 | Why? |
| Incidence | 6 | 2020 | 25622 | 0.11 | Why? |
| Female | 17 | 2021 | 380317 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.11 | Why? |
| Adolescent | 10 | 2020 | 86841 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.11 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.10 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.10 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.09 | Why? |
| Phenytoin | 1 | 2008 | 17 | 0.09 | Why? |
| Phenobarbital | 1 | 2008 | 22 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.09 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.08 | Why? |
| Malaria, Falciparum | 1 | 2011 | 377 | 0.08 | Why? |
| Immunogenicity, Vaccine | 2 | 2020 | 4624 | 0.08 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Kenya | 1 | 2008 | 887 | 0.07 | Why? |
| Analysis of Variance | 1 | 2008 | 950 | 0.07 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.07 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.06 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.06 | Why? |
| Data Interpretation, Statistical | 1 | 2008 | 657 | 0.06 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Anticonvulsants | 1 | 2008 | 634 | 0.06 | Why? |
| Male | 10 | 2020 | 367725 | 0.06 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.06 | Why? |
| Seizures | 1 | 2011 | 1163 | 0.06 | Why? |
| Immunization Programs | 3 | 2021 | 2006 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2020 | 31 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Smoking | 1 | 2014 | 3358 | 0.05 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.05 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2020 | 91 | 0.05 | Why? |
| Pertussis Vaccine | 1 | 2020 | 89 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Cost of Illness | 2 | 2020 | 1903 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 13720 | 0.04 | Why? |
| Malaria | 1 | 2008 | 1097 | 0.04 | Why? |
| Serotyping | 1 | 2017 | 154 | 0.04 | Why? |
| Canada | 2 | 2021 | 6018 | 0.04 | Why? |
| Capital Financing | 1 | 2017 | 35 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.04 | Why? |
| Technology Transfer | 1 | 2017 | 61 | 0.04 | Why? |
| Condoms | 1 | 2018 | 235 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Wales | 1 | 2019 | 758 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.04 | Why? |
| England | 2 | 2019 | 5116 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Retrospective Studies | 5 | 2019 | 105322 | 0.04 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| United States | 1 | 2021 | 46150 | 0.03 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2017 | 282 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Bias | 1 | 2018 | 1109 | 0.03 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Logistic Models | 2 | 2020 | 9089 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.03 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.03 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.03 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.03 | Why? |
| Norway | 1 | 2014 | 1004 | 0.02 | Why? |
| Uterine Cervical Neoplasms | 1 | 2018 | 842 | 0.02 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.02 | Why? |
| Hospitals, Pediatric | 1 | 2020 | 1792 | 0.02 | Why? |
| Confidence Intervals | 1 | 2011 | 744 | 0.02 | Why? |
| Aged | 2 | 2021 | 215776 | 0.02 | Why? |
| Sweden | 1 | 2014 | 1969 | 0.02 | Why? |
| Denmark | 1 | 2014 | 2654 | 0.02 | Why? |
| Adult | 3 | 2020 | 244371 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Netherlands | 1 | 2014 | 3533 | 0.02 | Why? |
| Cohort Studies | 1 | 2008 | 36005 | 0.02 | Why? |
| Prevalence | 2 | 2017 | 25773 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2008 | 43792 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2014 | 9893 | 0.01 | Why? |
| Republic of Korea | 1 | 2011 | 5858 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Critical Care | 1 | 2019 | 14081 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Middle Aged | 1 | 2014 | 270681 | 0.00 | Why? |
Sadarangani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(156)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(71)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_